

Rajesh Chavan

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/292527/publications.pdf>

Version: 2024-02-01

8
papers

77
citations

1937685

4
h-index

1720034

7
g-index

8
all docs

8
docs citations

8
times ranked

72
citing authors

#	ARTICLE	IF	CITATIONS
1	<p>Levonadifloxacin, a Novel Broad-Spectrum Anti-MRSA Benzoquinolizine Quinolone Agent: Review of Current Evidence</p>. Drug Design, Development and Therapy, 2019, Volume 13, 4351-4365.	4.3	44
2	WCK 4873 (Nafithromycin): Assessment of In Vitro Human CYP Inhibitory Potential of a Novel Lactone-Ketolide. Open Forum Infectious Diseases, 2016, 3, .	0.9	8
3	<i>In Vivo</i> Pharmacokinetic/Pharmacodynamic Targets of Levonadifloxacin against Staphylococcus aureus in a Neutropenic Murine Lung Infection Model. Antimicrobial Agents and Chemotherapy, 2019, 63, .	3.2	7
4	Safety, Tolerability, and Pharmacokinetics of Oral Nafithromycin (WCK 4873) after Single or Multiple Doses and Effects of Food on Single-Dose Bioavailability in Healthy Adult Subjects. Antimicrobial Agents and Chemotherapy, 2019, 63, .	3.2	7
5	Assessment of the <i>in vitro</i> cytochrome P450 (CYP) inhibition potential of nafithromycin, a next generation lactone ketolide antibiotic. Xenobiotica, 2021, 51, 251-261.	1.1	5
6	Assessment of <i>in vitro</i> inhibitory effects of novel anti MRSA benzoquinolizine fluoroquinolone WCK 771 (levonadifloxacin) and its metabolite on human liver cytochrome P450 enzymes. Xenobiotica, 2020, 50, 1149-1157.	1.1	4
7	Preclinical safety evaluation of nafithromycin (WCK 4873) with emphasis on liver safety in rat and dog. Regulatory Toxicology and Pharmacology, 2021, 122, 104889.	2.7	2
8	In-vitro antibacterial activity of Fosfomycin and Nitrofurantoin against Pseudomonas aeruginosa and Acinetobacter baumannii against clinical isolates collected from Indian tertiary care hospitals. Journal of Drug Delivery and Therapeutics, 2022, 12, 26-32.	0.5	0